 Patients with metastatic castration-resistant prostate cancer will be randomised 1:1 to either control group standard of care or intervention group CTC-guided treatment. All patients will commence first line chemotherapy with docetaxel three-weekly and will receive a minimum of 3 cycles of treatment before any recommendation to discontinue first-line docetaxel. 